CORRESP Filing
Akari Therapeutics Plc
Date: May 12, 2025 · CIK: 0001541157 · Accession: 0000950170-25-069161
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287012
Letter
Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 May 12, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed May 6, 2025 (File No. 333-287012) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, Plc (the “ Company ”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-287012) (the “ Registration Statement ”) be accelerated so that the Company’s Registration Statement will become effective at 4:05 P.M., Eastern Time, on May 14, 2025, or as soon thereafter as is practicable. Please contact Sam Zucker, Esq. of Goodwin Procter LLP, counsel to the Company, at (650) 752-3232 to provide notice of effectiveness, or if you have any questions or comments concerning this request. [ Remainder of the page intentionally left blank ]
Very truly yours,
AKARI THERAPEUTICS, PLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP Akari Therapeutics, Plc 22 Boston Wharf Road, FL 7 Boston, MA 02210 May 12, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Akari Therapeutics, Plc Registration Statement on Form S-3 Filed May 6, 2025 (File No. 333-287012) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, Plc (the “ Company ”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-287012) (the “ Registration Statement ”) be accelerated so that the Company’s Registration Statement will become effective at 4:05 P.M., Eastern Time, on May 14, 2025, or as soon thereafter as is practicable. Please contact Sam Zucker, Esq. of Goodwin Procter LLP, counsel to the Company, at (650) 752-3232 to provide notice of effectiveness, or if you have any questions or comments concerning this request. [ Remainder of the page intentionally left blank ] Very truly yours, AKARI THERAPEUTICS, PLC By: /s/ Abizer Gaslightwala Name: Abizer Gaslightwala Title: President and Chief Executive Officer